Medicamen Organics LimitedMEDIORGCorporate

Pharmaceuticals - Indian - Formulations Latest results: Mar 2026 6 quarters of data

₹26.75

MCap ₹31 Cr

Medicamen Organics Limited — Stock analysis & AI research Medicamen Organics Limited — Seasonality — best & worst months Medicamen Organics Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹5 Cr

Sales · Mar 2026

-77.5% YoY

₹-6 Cr

Operating Profit · Mar 2026

-316.0% YoY

-132.0%

OPM % · Mar 2026

-1063.5% YoY

₹-5 Cr

Net Profit · Mar 2026

-383.0% YoY

₹-4.09

EPS · Mar 2026

-372.7% YoY

📝 Medicamen Organics Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Medicamen Organics Limited reported revenue of ₹5 crore for the quarter ended March 2026 (Q4 FY26), down 77.5% from ₹20 crore in the same quarter last year.

The company reported a net loss of ₹5 crore, against a net profit of ₹2 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-4.09.

Operating profit stood at ₹-6 crore — an operating margin (OPM) of -132.0%, compared with 13.7% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹22 crore with a net loss of ₹3 crore.

Valuation snapshot

At the current price of ₹26.75, MEDIORG has a market capitalisation of ₹31 crore.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 19th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, domestic institutional investors (DIIs) 1.64%, promoters held 59.73%, foreign institutional investors (FIIs) 0.07%, public shareholders 38.56% of Medicamen Organics Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹31 Cr

Current Price ?

₹26.8

P/E ?

N/A

Industry P/E ?

21.30

P/B ?

1.09

P/S ?

1.45

P/FCF ?

-5.40

Enterprise Value ?

₹45 Cr

EV/EBITDA ?

-16.07

PEG ?

N/A

Earnings Yield ?

-8.2%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹22 Cr

OPM ?

-12.9%

Profit after tax (TTM) ?

₹-3 Cr

EPS (TTM) ?

₹-2.60

ROCE ?

-8.5%

ROE ?

-10.6%

ROA ?

-6.0%

Growth

Sales — latest qtr ?

₹5 Cr

PAT — latest qtr ?

₹-5 Cr

YoY qtr sales growth ?

-77.5%

YoY qtr profit growth ?

-383.0%

Sales growth (3y) ?

-1%

Sales growth (5y) ?

-3%

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹14 Cr

Debt to Equity ?

0.48

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

59.73%

Change in promoter holding ?

0.04%

Pledged percentage ?

N/A

Market

Return 3 months ?

16.8%

Return 6 months ?

-9.9%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025	Mar 2026	YoY %	QoQ %
Sales	11	14	17	20	17	5	-77.5%	—
Operating Profit	2	2	3	3	3	-6	-316.0%	—
Other Income	1	0	0	0	0	0	-60.0%	—
Interest	0	0	0	0	0	0	+27.6%	—
Depreciation	0	0	0	0	0	0	+29.7%	—
Profit Before Tax	3	2	2	2	3	-7	-413.6%	—
Net Profit	1	1	2	2	2	-5	-383.0%	—
EPS	1.70	1.47	1.29	1.50	1.66	-4.09	-372.7%	—
OPM %	21.3%	16.7%	15.2%	13.7%	19.2%	-132.0%	-1063.5%	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	6.00	8.60	11.70	12.17	+4.0%
Reserves	2.98	6.66	18.02	16.64	-7.7%
Borrowings	11.79	12.66	12.13	13.69	+12.9%
Other Liabilities	11.82	10.52	15.60	7.99	-48.8%
Total Liabilities	32.59	38.44	57.45	50.49	-12.1%
Fixed Assets	10.87	10.35	10.13	13.28	+31.1%
CWIP	0.00	0.15	2.22	0.09	-95.9%
Investments	0.00	0.00	0.27	0.27	+0.0%
Other Assets	21.72	27.94	44.83	36.85	-17.8%
Total Assets	32.59	38.44	57.45	50.49	-12.1%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-0.58	-3.66	-4.91	-4.15	+15.5%
Cash from Investing Activity	-0.28	-0.34	-2.62	-1.63	+37.8%
Cash from Financing Activity	0.94	4.01	10.25	3.10	-69.8%
Net Cash Flow	0.07	0.01	2.72	-2.67	-198.2%
Free Cash Flow	-0.87	-4.01	-7.36	-5.80	+21.2%
CFO/OP	-28%	-73%	-87%	145%	+266.7%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	177.47	241.21	243.56	302.96	+24.4%
Inventory Days	225.01	244.39	228.39	246.36	+7.9%
Days Payable	329.82	281.81	355.85	129.40	-63.6%
Cash Conversion Cycle	72.66	203.80	116.10	419.92	+261.7%
Working Capital Days	-25.71	74.24	137.77	245.47	+78.2%
ROCE %	10.22%	16.59%	14.10%	-8.54%	-160.6%

👥 Shareholding (latest 4 periods)

Metric	Sep 2024	Mar 2025	Sep 2025	Mar 2026	% Chg
DIIs	3.76%	3.79%	3.69%	1.64%	-55.6%
Promoters	59.69%	59.73%	59.73%	59.73%	+0.0%
FIIs	0.14%	0.07%	0.07%	0.07%	+0.0%
Public	36.41%	36.41%	36.51%	38.56%	+5.6%
No. of Shareholders	379	460	507	540	+6.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SHILPAMED Shilpa Medicare	₹1,032.00	20,184	67.5	1,683	297	28.4%	17.7%	47.7%	454.9%	44.9%	115.2%
2	MARKSANS Marksans Pharma	₹332.50	15,068	29.1	3,171	521	22.5%	16.4%	12.5%	9.7%	35.6%	174.8%
3	BLISSGVS Bliss GVS	₹680.50	7,236	52.9	1,005	142	19.7%	14.1%	14.4%	48.7%	37.6%	15.8%
4	JSLL Jeena Sikho	₹507.55	6,309	26.7	852	236	42.6%	27.7%	17.1%	85.5%	28.8%	28.0%
5	SENORES Senores Pharmaceuticals	₹1,327.50	6,114	46.6	692	131	29.5%	19.0%	63.0%	108.7%	30.6%	43.8%
6	WINDLAS Windlas Biotech	₹1,129.50	2,331	35.7	942	66	11.1%	7.1%	18.9%	9.0%	18.1%	-0.1%
7	VENUSREM Venus Remedies	₹1,651.10	2,210	19.0	811	117	20.4%	14.4%	17.9%	127.9%	35.6%	139.3%
8	SYNCOMF Syncom Formulations	₹23.44	2,203	1.3	12,547	1,729	15.2%	13.8%	2566.9%	3386.8%	7.4%	57.7%
9	HESTERBIO Hester Biosciences	₹2,187.90	1,861	13.6	318	137	30.8%	43.0%	4.7%	101.2%	-8.4%	460.8%
10	AMRUTANJAN Amrutanjan Health	₹489.00	1,413	26.2	512	54	14.4%	10.5%	11.0%	1.3%	9.5%	-45.4%
11	LINCOLN Lincoln Pharmaceuticals	₹601.50	1,205	12.5	694	97	14.6%	14.0%	7.6%	7.2%	15.1%	30.9%
12	BAFNAPH Bafna Pharmaceuticals	₹301.45	713	91.6	143	8	8.2%	5.5%	3.3%	166.8%	-23.2%	-97.8%
13	KILITCH Kilitch Drugs	₹198.00	692	16.1	237	29	15.3%	12.3%	18.7%	20.1%	4.0%	-13.0%
14	MEDICAMEQ Medicamen Biotech	₹323.80	439	1.3	9,516	381	10.1%	4.0%	5751.8%	3308.0%	11.3%	15.3%
15	QUESTLAB Quest Laboratories	₹137.50	225	13.7	150	16	12.7%	11.0%	25.8%	34.9%	-30.2%	47.9%
16	JFLLIFE Jfl Life	₹51.05	168	24.7	131	7	9.1%	5.2%	60.2%	53.1%	-4.2%	48.5%
17	ZENITHDRUG Zenith	₹78.45	135	41.7	171	4	7.0%	2.3%	—	—	40.9%	100.0%
18	ALPA Alpa Laboratories	₹62.32	131	29.6	111	4	1.7%	4.0%	-5.9%	-22.5%	25.2%	-91.7%
19	MEDIORG Medicamen	₹101.45	119	—	22	-3	-12.9%	-14.0%	—	—	-77.5%	-383.0%
20	BIOFILCHEM Biofil Chemicals	₹33.13	54	110.4	34	0	2.3%	1.4%	-15.0%	405.5%	92.1%	-95.5%

❓ Frequently asked questions

What was Medicamen Organics Limited's revenue in Q4 FY26?